Carole Longson

594 total citations
22 papers, 265 citations indexed

About

Carole Longson is a scholar working on Economics and Econometrics, Molecular Biology and Oncology. According to data from OpenAlex, Carole Longson has authored 22 papers receiving a total of 265 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Carole Longson's work include Health Systems, Economic Evaluations, Quality of Life (11 papers), Pharmaceutical Economics and Policy (5 papers) and Cardiac pacing and defibrillation studies (2 papers). Carole Longson is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (11 papers), Pharmaceutical Economics and Policy (5 papers) and Cardiac pacing and defibrillation studies (2 papers). Carole Longson collaborates with scholars based in United Kingdom, Canada and United States. Carole Longson's co-authors include David Barnett, Andrew Stevens, Stephanie Phillips, Peter Littlejohns, John C. W. Lim, Sean Tunis, Gigi Hirsch, Reiner Banken, L G Baird and Janet Woodcock and has published in prestigious journals such as The Lancet Oncology, Clinical Cancer Research and European Heart Journal.

In The Last Decade

Carole Longson

21 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carole Longson United Kingdom	10	138	55	43	28	26	22	265
Julia Caroline Michaeli Germany	9	74 0.5×	20 0.4×	15 0.3×	27 1.0×	10 0.4×	23	249
Michaela Blundell United Kingdom	5	83 0.6×	14 0.3×	27 0.6×	44 1.6×	5 0.2×	6	300
Alex Simpson Switzerland	7	31 0.2×	29 0.5×	12 0.3×	25 0.9×	6 0.2×	22	246
Mingjun Rui China	8	85 0.6×	15 0.3×	26 0.6×	118 4.2×	10 0.4×	20	268
Stephanie O. Omokaro United States	4	34 0.2×	10 0.2×	18 0.4×	31 1.1×	40 1.5×	5	260
L. Silva Miguel Portugal	8	77 0.6×	23 0.4×	16 0.4×	24 0.9×	9 0.3×	40	153
Deanna Cross United States	10	19 0.1×	18 0.3×	23 0.5×	74 2.6×	15 0.6×	24	288
Miranda L. G. Hallquist United States	10	41 0.3×	8 0.1×	54 1.3×	13 0.5×	11 0.4×	14	311
Roy Lan United States	10	21 0.2×	58 1.1×	23 0.5×	25 0.9×	6 0.2×	23	331
Chaoqun Mei United States	8	32 0.2×	93 1.7×	4 0.1×	23 0.8×	14 0.5×	14	254

Countries citing papers authored by Carole Longson

Since Specialization

Citations

This map shows the geographic impact of Carole Longson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carole Longson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carole Longson more than expected).

Fields of papers citing papers by Carole Longson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carole Longson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carole Longson. The network helps show where Carole Longson may publish in the future.

Co-authorship network of co-authors of Carole Longson

This figure shows the co-authorship network connecting the top 25 collaborators of Carole Longson. A scholar is included among the top collaborators of Carole Longson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carole Longson. Carole Longson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baird, L G, Reiner Banken, Finn Børlum Kristensen, et al.. (2014). Accelerated Access to Innovative Medicines for Patients in Need. Clinical Pharmacology & Therapeutics. 96(5). 559–571. 64 indexed citations

Longson, Carole. (2014). HTAI POLICY FORUM: KEEPING HTA ON TRACK. International Journal of Technology Assessment in Health Care. 30(3). 251–252. 3 indexed citations

Campbell, Bruce, et al.. (2013). How can we get high quality routine data to monitor the safety of devices and procedures?. BMJ. 346(may07 3). f2782–f2782. 10 indexed citations

Henshall, Chris, et al.. (2013). Understanding the Role and Evidence Expectations of Health Technology Assessment and Coverage/Payer Bodies: What Are They Looking for, and How and Why Does This Differ From What Regulators Require?. Therapeutic Innovation & Regulatory Science. 48(3). 341–346. 3 indexed citations

Stevens, Andrew & Carole Longson. (2013). At the Center of Health Care Policy Making. Medical Decision Making. 33(3). 320–324. 11 indexed citations

Phillips, Stephanie, et al.. (2012). NI1 Three Years of Nice Scientific Advice: Comprehensive Analysis of Requests to the Programme. Value in Health. 15(7). A278–A278. 1 indexed citations

Longson, Carole. (2012). Foreward by the Director of the Centre for Health Technology Evaluation. Journal of the Royal Society of Medicine. 105(1_suppl). 2–2. 1 indexed citations

Hill, Ruaraidh, Hyemoon Chung, Elisabeth George, Carole Longson, & Andrew Stevens. (2010). Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidance. Heart. 96(17). 1407–1408. 14 indexed citations

Longson, Carole. (2010). Re: Single technology appraisal (STA): Denosumab for the prevention of osteoporotic fractures in postmenopausal women - Appraisal consultation document. 1 indexed citations

10.

Littlejohns, Peter, et al.. (2009). 10 years of NICE: still growing and still controversial. The Lancet Oncology. 10(4). 417–424. 26 indexed citations

11.

Chung, Helen, et al.. (2009). Lenalidomide for the treatment of relapsed multiple myeloma. The Lancet Oncology. 10(7). 647–648. 3 indexed citations

12.

Chung, Helen, et al.. (2008). Rituximab for follicular non-Hodgkin lymphoma. The Lancet Oncology. 9(4). 320–321. 4 indexed citations

13.

Tucker, Helen, Elisabeth George, David Barnett, & Carole Longson. (2008). NICE Technology Appraisal on Stapled Haemorrhoidopexy for the Treatment of Haemorrhoids. Annals of The Royal College of Surgeons of England. 90(1). 82–84. 5 indexed citations

14.

Boysen, Meindert, et al.. (2008). Erlotinib for the treatment of non-small-cell lung cancer. The Lancet Oncology. 10(1). 15–16. 17 indexed citations

15.

Barnett, David, Stephanie Phillips, & Carole Longson. (2007). Cardiac resynchronisation therapy for the treatment of heart failure: NICE technology appraisal guidance. Heart. 93(9). 1134–1135. 42 indexed citations

16.

Kearney, Patricia M., Günter Breithardt, Carole Longson, et al.. (2006). Improving patient access to novel medical technologies in Europe. European Heart Journal. 27(7). 882–885. 5 indexed citations

17.

Barnett, David, Andrew Stevens, & Carole Longson. (2006). Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK. The Lancet Oncology. 7(10). 807–808. 5 indexed citations

18.

Littlejohns, Peter, David Barnett, & Carole Longson. (2003). The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence. The Lancet Oncology. 4(4). 242–250. 12 indexed citations

19.

Longson, Carole, et al.. (1998). Specific increase in size of lamina II pyramidal cells in the entorhinal cortex in schizophrenia. Schizophrenia Research. 29(1-2). 87–88.

20.

Longson, Carole, et al.. (1997). Localization of CAM II Kinase‐α, GAD, GluR2 and GABAA Receptor Subunit mRNAs in the Human Entorhinal Cortex. European Journal of Neuroscience. 9(4). 662–675. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact